Giuseppe Giannini

Giuseppe Giannini

Auto-generated profile, based on publicly available information

Giuseppe Giannini


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2016 in Future Medicinal Chemistry
Verified
Journal Article
Open access
SRSilvia Rivara
Silvia Rivara
FMFerdinando M Milazzo
Ferdinando M Milazzo
GGGiuseppe Giannini
Giuseppe Giannini
In recent years, heparanase has attracted considerable attention as a promising target for innovative pharmacological applications. Heparanase is a multifaceted protein endowed with enzymatic activity, as an endo-β-D-glucuronidase, and nonenzymatic functions. It is responsible for the cleavage of heparan sulfate side chains of proteoglycans, resulting in structural alterations of the extracellular matrix. Heparanase appears to be involved in major human diseases, from the most studied tumors to chronic inflammation, diabetic nephropathy, bone osteolysis, thrombosis and atherosclerosis, in addition to more recent investigation in various rare diseases. The present review provides an overview on heparanase, its biological role, inhibitors and possible clinical applications, covering the latest findings in these areas.

1 July 2012 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
GGGiuseppe Giannini
Giuseppe Giannini
WCWalter Cabri
Walter Cabri
CFCaterina Fattorusso
Caterina Fattorusso
Manuela RodriquezManuela Rodriquez
Manuela Rodriquez
Histone deacetylase inhibitors (HDACis) are one of the last frontiers in pharmaceutical research. Several classes of HDACi have been identified. Although more than 20 HDACi are under preclinical and clinical investigation as single agents and in combination therapies against different cancers, just two of them were approved by the US FDA: Zolinza(®) and Istodax(®), both licensed for the treatment of cutaneous T-cell lymphoma, the latter also of peripheral T-cell lymphoma. Since HDAC enzymes act by forming multiprotein complexes (clusters), containing cofactors, the main problem in designing new HDACi is that the inhibition activity evaluated on isolated enzyme isoforms does not match the in vivo outcomes. In the coming years, the research will be oriented toward a better understanding of the functioning of these protein complexes as well as the development of new screening assays, with the final goal to obtain new drug candidates for the treatment of cancer.

17 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MTMaurizio Taddei
Maurizio Taddei
SFSerena Ferrini
Serena Ferrini
LGLuca Giannotti
Luca Giannotti
MCMassimo Corsi
Massimo Corsi
Fabrizio ManettiFabrizio Manetti
Fabrizio Manetti
WCWalter Cabri
Walter Cabri

30 November 2009 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
PGPaola Galletti
Paola Galletti
AQArianna Quintavalla
Arianna Quintavalla
CVCaterina Ventrici
Caterina Ventrici
GGGiuseppe Giannini
Giuseppe Giannini
WCWalter Cabri
Walter Cabri
DGDaria Giacomini
Daria Giacomini

1 May 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
GGGiuseppe Giannini
Giuseppe Giannini
MMMauro Marzi
Mauro Marzi
MMMaria Di Marzo
Maria Di Marzo
GBGianfranco Battistuzzi
Gianfranco Battistuzzi
RPRiccardo Pezzi
Riccardo Pezzi
CPClaudio Pisano
Claudio Pisano

8 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GGGiuseppe Giannini
Giuseppe Giannini
LVLoredana Vesci
Loredana Vesci
GBGianfranco Battistuzzi
Gianfranco Battistuzzi
DVDavide Vignola
Davide Vignola
FMFerdinando M. Milazzo
Ferdinando M. Milazzo
WCWalter Cabri
Walter Cabri